Nitensidine A, a guanidine alkaloid from Pterogyne nitens, induces osteoclastic cell death

Cytotechnology

Volumn 67, Issue 4, 2015, Pages 585-592

  Tajima, Yasuhiro ^a   Murase, Hayato ^a   Satake, Kazuhiro ^a   Mitani, Yuji ^a   Regasini, Luis Octavio ^b   da Silva Bolzani, Vanderlan ^b   Efferth, Thomas ^c   Nakagawa, Hiroshi ^a  

^a CHUBU UNIVERSITY   (Japan)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Cytotoxicity; Guanidine alkaloids; Osteoclast; Pterogyne nitens; Structure and activity relationship

Indexed keywords

ALKALOID DERIVATIVE; APOPTOSIS INDUCING FACTOR; GALEGINE; GUANIDINE DERIVATIVE; NITENSIDINE A; NITENSIDINE AT; NITENSIDINE AU; NITROGEN; OXYGEN; PTEROGYNIDINE; PTEROGYNINE; SULFUR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIOSTEOCLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW OSTEOCLAST CELL; BONE METABOLISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG ACTIVITY; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG EFFICACY; GIANT CELL; HUMAN; HUMAN CELL; IC50; ISOPRENYLATION; MALE; MEDICINAL PLANT; MOUSE; NONHUMAN; OSTEOLYSIS; PHARMACOPHORE; POLYMERIZATION; PTEROGYNE NITENS; STRUCTURE ACTIVITY RELATION;

PTEROGYNE NITENS;

EID: 84931562137     PISSN: 09209069     EISSN: 15730778     Source Type: Journal    
DOI: 10.1007/s10616-013-9590-2     Document Type: Article

References (29)

1. Bolzani VS, Gunatilaka AA, Kingston DG (1995) Bioactive guanidine alkaloids from Pterogyne nitens. J Nat Prod 58:1638–1688
2. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342
3. Chambers TJ (2000) Regulation of the differentiation and function of osteoclasts. J Pathol 192:4–13
4. Duarte RA, Mello ER, Araki C, Bolzani Vda S, Siqueira e Silva DH, Regasini LO, Silva TG, de Morais MC, Ximenes VF, Soares CP (2010) Alkaloids extracted from Pterogyne nitens induce apoptosis in malignant breast cell line. Tumour Biol 31:513–522
5. Edwards JR, Mundy GR (2011) Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol 7:235–243
6. Felix R, Cecchini MG, Hofstetter W, Elford PR, Stutzer A, Fleisch H (1990) Impairment of macrophage colony-stimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse. J Bone Miner Res 5:781–789
7. Fernandes DC, Regasini LO, Vellosa JC, Pauletti PM, Castro-Gamboa I, Bolzani VS, Oliveira OM, Silva DH (2008) Myeloperoxidase inhibitory and radical scavenging activities of flavones from Pterogyne nitens. Chem Pharm Bull (Tokyo) 56:723–726
8. Fuller K, Lean JM, Bayley KE, Wani MR, Chambers TJ (2000) A role for TGFβ1 in osteoclast differentiation and survival. J Cell Sci 113:2445–2453
9. Kaneda T, Nojima T, Nakagawa M, Ogasawara A, Kaneko H, Sato T, Mano H, Kumegawa M, Hakeda Y (2000) Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. J Immunol 165:4254–4263
10. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176
11. Mochizuki A, Takami M, Kawawa T, Suzumoto R, Sasaki T, Shiba A, Tsukasaki H, Zhao B, Yasuhara R, Suzawa T, Miyamoto Y, Choi Y, Kamijo R (2006) Identification and characterization of the precursors committed to osteoclasts induced by TNF-related activation-induced cytokine/receptor activator of NF-kappa B ligand. J Immunol 177:4360–4368
12. Nakagawa H, Wachi M, Woo JT, Kato M, Kasai S, Takahashi F, Lee IS, Nagai K (2002) Fenton reaction is primarily involved in a mechanism of (−)-epigallocatechin-3-gallate to induce osteoclastic cell death. Biochem Biophys Res Commun 292:94–101
13. Nakagawa H, Takami M, Udagawa N, Sawae Y, Suda K, Sasaki T, Takahashi N, Wachi M, Nagai K, Woo JT (2003) Destruxins, cyclodepsipeptides, block the formation of actin rings and prominent clear zones and ruffled borders in osteoclasts. Bone 33:443–455
14. Nakagawa H, Hasumi K, Takami M, Aida-Hyugaji S, Woo JT, Nagai K, Ishikawa T, Wachi M (2007) Identification of two biologically crucial hydroxyl groups of (−)-epigallocatechin gallate in osteoclast culture. Biochem Pharmacol 73:34–43
15. Nakagawa H, Wakabayashi-Nakao K, Tamura A, Toyoda Y, Koshiba S, Ishikawa T (2009) Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2. FEBS J 276:7237–7252
16. Regasini LO, Vellosa JC, Silva DH, Furlan M, de Oliveira OM, Khalil NM, Brunetti IL, Young MC, Barreiro EJ, Bolzani VS (2008) Flavonols from Pterogyne nitens and their evaluation as myeloperoxidase inhibitors. Phytochemistry 69:1739–1744
17. Regasini LO, Castro-Gamboa I, Silva DH, Furlan M, Barreiro EJ, Ferreira PM, Pessoa C, Lotufo LV, de Moraes MO, Young MC, Bolzani Vda S (2009) Cytotoxic guanidine alkaloids from Pterogyne nitens. J Nat Prod 72:473–476
18. Regasini LO, Pivatto M, Scorzoni L, Benaducci T, Fusco-Almeida A, Giannini M, Barreiro EJ, Silva D, Bolzani Vda S (2010) Antimicrobial activity of Pterogyne nitens Tul., Fabaceae, against opportunistic fungi. Rev Bras Farmacogn 20:706–711
19. Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289:1508–1514
20. Sells Galvin RJ, Gatlin CL, Horn JW, Fuson TR (1999) TGF-beta enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem Biophys Res Commun 265:233–239
21. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504–1508
22. Tomimori Y, Mori K, Koide M, Nakamichi Y, Ninomiya T, Udagawa N, Yasuda H (2009) Evaluation of pharmaceuticals with a novel 50-h animal model of bone loss. J Bone Miner Res 24:1194–1205
23. Venkatachalam TK, Qazi S, Samuel P, Uckun FM (2003) Inhibition of mast cell leukotriene release by thiourea derivatives. Bioorg Med Chem Lett 13:485–488
24. Wattel A, Kamel S, Mentaverri R, Lorget F, Prouillet C, Petit JP, Fardelonne P, Brazier M (2003) Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. Biochem Pharmacol 65:35–42
25. Woo JT, Nakagawa H, Notoya M, Yonezawa T, Udagawa N, Lee IS, Ohnishi M, Hagiwara H, Nagai K (2004) Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts. Biol Pharm Bull 27:504–509
26. Yan T, Riggs BL, Boyle WJ, Khosla S (2001) Regulation of osteoclastogenesis and RANK expression by TGF-beta1. J Cell Biochem 83:320–325
27. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602
28. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD, Nishikawa S (1990) The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345:442–444
29. Zhao B, Takami M, Yamada A, Wang X, Koga T, Hu X, Tamura T, Ozato K, Choi Y, Ivashkiv LB, Takayanagi H, Kamijo R (2009) Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med 15:1066–1071